î
î
Pharvaris NV
PHVS23.460USD
-0.320-1.35%
āđāļ§āļĨāļēāļāļģāļāļēāļĢāļāļĨāļēāļÂ ïžETïžāļĢāļēāļāļēāļĨāđāļēāļāđāļē 15 āļāļēāļāļĩ
1.28BāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
āļāļēāļāļāļļāļP/E TTM
î
āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ Pharvaris NV āļāļĢāļīāļĐāļąāļ
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
āļāđāļāļĄāļđāļĨāļāļĢāļīāļĐāļąāļî
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPHVS
āļāļ·āđāļāļāļĢāļīāļĐāļąāļPharvaris NV
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 05, 2021
āļāļĩāļāļĩāđāļMr. Berndt Modig, CPA
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ- -
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļFeb 05
āļāļĩāđāļāļĒāļđāđEmmy Noetherweg 2
āđāļĄāļ·āļāļLEIDEN
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ Global Select Consolidated
āļāļĢāļ°āđāļāļĻNetherlands
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ2333 BK
āđāļāļĢāļĻāļąāļāļāđ31712036410
āđāļ§āđāļāđāļāļāđhttps://pharvaris.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPHVS
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 05, 2021
āļāļĩāļāļĩāđāļMr. Berndt Modig, CPA
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļî
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
āļŠāļąāļāļŠāđāļ§āļāļāļāļāļĢāļēāļĒāđāļāđ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļāļēāļĄāļāļļāļĢāļāļīāļ
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļŠāļāļīāļāļīāļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 19 āļŠ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 19 āļŠ.āļ.
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
General Atlantic LLC
11.76%
Fidelity Management & Research Company LLC
8.47%
Foresite Capital Management, LLC
6.89%
VenBio Partners LLC
6.70%
Viking Global Investors LP
5.70%
āļāļ·āđāļ āđ
60.49%
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
General Atlantic LLC
11.76%
Fidelity Management & Research Company LLC
8.47%
Foresite Capital Management, LLC
6.89%
VenBio Partners LLC
6.70%
Viking Global Investors LP
5.70%
āļāļ·āđāļ āđ
60.49%
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Private Equity
25.72%
Investment Advisor
16.37%
Hedge Fund
14.25%
Venture Capital
13.60%
Investment Advisor/Hedge Fund
6.26%
Individual Investor
5.32%
Research Firm
0.08%
Bank and Trust
0.04%
Pension Fund
0.03%
āļāļ·āđāļ āđ
18.34%
āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļî
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 1 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 1 āļ.āļ.
āļāđāļ§āļāđāļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļāļēāļ
āļāļģāļāļ§āļāļŠāļāļēāļāļąāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
2025Q2
125
52.21M
81.51%
-1.38M
2025Q1
125
53.89M
99.06%
+200.61K
2024Q4
123
53.45M
98.98%
+218.03K
2024Q3
114
53.86M
99.73%
+1.03M
2024Q2
83
52.08M
96.43%
-141.66K
2024Q1
76
49.63M
98.30%
-831.88K
2023Q4
69
47.76M
94.74%
+8.60M
2023Q3
54
36.05M
91.51%
-2.92M
2023Q2
53
35.78M
91.11%
+3.65M
2023Q1
61
28.67M
84.75%
-3.62M
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļīāļāļāļĢāļĢāļĄāļāļđāđāļāļ·āļāļŦāļļāđāļî
āļāļ·āđāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
āđāļāļĨāļĩāđāļĒāļ%
āļ§āļąāļāļāļĩāđ
General Atlantic LLC
7.53M
13.82%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.40M
9.9%
--
--
Mar 31, 2025
Foresite Capital Management, LLC
4.41M
8.09%
+12.70K
+0.29%
Mar 31, 2025
VenBio Partners LLC
4.29M
7.87%
--
--
Mar 31, 2025
Viking Global Investors LP
3.65M
6.7%
--
--
Mar 31, 2025
EQT Life Sciences
3.56M
6.53%
--
--
Apr 01, 2025
Bain Capital Life Sciences Investors, LLC
3.30M
6.06%
--
--
Mar 31, 2025
VR Adviser, LLC
3.11M
5.71%
-107.41K
-3.34%
Mar 31, 2025
Deerfield Management Company, L.P.
2.02M
3.7%
--
--
Mar 31, 2025
Commodore Capital LP
1.91M
3.51%
--
--
Mar 31, 2025
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ETF āļāļĩāđāđāļāļĩāđāļĒāļ§āļāđāļāļî
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļļāļāļāļĩāđ 6 āļŠ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļļāļāļāļĩāđ 6 āļŠ.āļ.
āļāļ·āđāļ
āļŠāļąāļāļŠāđāļ§āļ
Virtus LifeSci Biotech Clinical Trials ETF
0.92%
ALPS Medical Breakthroughs ETF
0.65%
iShares MSCI Netherlands ETF
0.18%
iShares MSCI Europe Small-Cap ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
iShares MSCI EAFE Small-Cap ETF
0.01%
First Trust IPOX Europe Equity Opportunities ETF
0%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0%
Avantis International Small Cap Equity ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
āļŠāļąāļāļŠāđāļ§āļ0.92%
ALPS Medical Breakthroughs ETF
āļŠāļąāļāļŠāđāļ§āļ0.65%
iShares MSCI Netherlands ETF
āļŠāļąāļāļŠāđāļ§āļ0.18%
iShares MSCI Europe Small-Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.02%
SPDR S&P International Small Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.02%
iShares MSCI EAFE Small-Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
First Trust IPOX Europe Equity Opportunities ETF
āļŠāļąāļāļŠāđāļ§āļ0%
Xtrackers MSCI Eurozone Hedged Eqty ETF
āļŠāļąāļāļŠāđāļ§āļ0%
Avantis International Small Cap Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0%
Fidelity Nasdaq Composite Index ETF
āļŠāļąāļāļŠāđāļ§āļ0%
āđāļāļīāļāļāļąāļāļāļĨî
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
āļ§āļąāļāļāļĩāđ
āđāļāļīāļāļāļąāļāļāļĨ
āļ§āļąāļāļāļĩāđāļāļąāļāļāļķāļ
āļ§āļąāļāļāļĩāđāļāļģāļĢāļ°āđāļāļīāļ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļāļēāļĢāđāļāđāļāļŦāļļāđāļî
āļ§āļąāļāļāļĩāđ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļ§āļąāļāļāļĩāđ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
